Vitrolife AB

Vitrolife AB

10.25
USD
+0.75
(+7.84%)
-3.83EPS
1.16BMarket Cap
Jan 28Next Earn

Total Valuation

USD

As of September 30, 2026, Vitrolife AB carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.16B
Enterprise Value1.24B

Important Dates

Vitrolife AB's next confirmed earnings release is scheduled for January 28, 2027.

Earnings Date1/28/2027

Share Statistics

As of September 30, 2026, Vitrolife AB has 127.21M shares outstanding.

Shares Outstanding127.21M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 1.42.

PS Ratio3.42
PB Ratio1.42
P/TBV Ratio-45.85
P/FCF Ratio17.76
P/OCF Ratio16.90

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.24B versus a market cap of 1.16B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.61

Financial Position

As of September 30, 2026, Vitrolife AB maintains a current ratio of 3.68, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

Current Ratio3.68
Quick Ratio1.40
Debt / Equity21.25
Debt / EBITDA-0.36

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 298,783.97 in revenue per employee across its workforce of 1,151.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee298,783.97
Employee Count1,151.00

Taxes

USD

Over the twelve months ended September 30, 2026, Vitrolife AB recorded 14.40M in income tax expense. The company reported a pretax loss of -481.60M and -495.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax14.40M

Stock Price Statistics

USD

As of the close on October 14, 2026, Vitrolife AB's stock has declined approximately 31.70% over the past 52 weeks.

52-Week Price Change-31.70%
50-Day Moving Average18.12

Income Statement

USD

Over the twelve months ended September 30, 2026, Vitrolife AB generated 343.90M in revenue and converted that into -495.70M in net income, yielding earnings per share of -3.83. EBITDA reached -474.20M, while operating income came in at -474.20M.

Revenue343.90M
Gross Profit204.00M
Operating Income-474.20M
Pretax Income-481.60M
Net Income-495.70M
EBITDA-474.20M
EBIT-474.20M
Earnings Per Share (EPS)-3.83

Balance Sheet

USD

As of September 30, 2026, Vitrolife AB holds 86.00M in cash and equivalents against 172.50M in total debt, resulting in a net debt position of 74.30M. Total book value stands at 811.80M, with working capital of 164.40M providing operational flexibility.

Cash & Cash Equivalents86.00M
Total Debt172.50M
Net Debt74.30M
Equity (Book Value)811.80M
Book Value Per Share6.38
Working Capital164.40M

Cash Flow

USD

Vitrolife AB produced 69.60M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.40M in capital expenditures, free cash flow totaled 66.20M - equivalent to 0.51 per share.

Operating Cash Flow69.60M
Capital Expenditures-3.40M
Free Cash Flow66.20M
FCF Per Share0.51

Margins

Over the twelve months ended September 30, 2026, Vitrolife AB posted a gross margin of 59.32, reflecting its pricing power and cost economics. The operating margin of -137.89 and net profit margin of -144.14 provide insight into operational efficiency.

Gross Margin59.32
Operating Margin-137.89
Pretax Margin-140.04
Profit Margin-144.14
EBITDA Margin-137.89

Dividends & Yields

USD

Over the twelve months ended September 30, 2026, Vitrolife AB paid dividends of 0.12 per share. The dividend payout ratio of -3.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vitrolife AB shareholders.

Dividend Per Share0.12
Payout Ratio-3.00
Shareholder Yield6.50
FCF Yield5.63

Stock Splits

Vitrolife AB's most recent stock split took place on June 1, 2018 with a 4:5 split ratio.

Last Split Date6/1/2018
Split Ratio4:5

Scores

As of September 30, 2026, Vitrolife AB has an Altman Z-Score of -4.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-4.37